Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo

Xi Ping Huang, Tao Che, Thomas J. Mangano, Valerie Le Rouzic, Ying Xian Pan, Susruta Majumdar, Michael D. Cameron, Michael H. Baumann, Gavril W. Pasternak, Bryan L. Roth

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

W-18 (4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide) and W-15 (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide) represent two emerging drugs of abuse chemically related to the potent opioid agonist fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide). Here, we describe the comprehensive pharmacological profiles of W-18 and W-15, as examination of their structural features predicted that they might lack opioid activity. We found W-18 and W-15 to be without detectible activity at μ, δ, κ, and nociception opioid receptors in a variety of assays. We also tested W-18 and W-15 for activity as allosteric modulators at opioid receptors and found them devoid of significant positive or negative allosteric modulatory activity. Comprehensive profiling at essentially all the druggable GPCRs in the human genome using the PRESTO-Tango platform revealed no significant activity. Weak activity at the sigma receptors and the peripheral benzodiazepine receptor was found for W-18 (Ki = 271 nM). W-18 showed no activity in either the radiant heat tail-flick or the writhing assays and also did not induce classical opioid behaviors. W-18 is extensively metabolized, but its metabolites also lack opioid activity. Thus, although W-18 and W-15 have been suggested to be potent opioid agonists, our results reveal no significant activity at these or other known targets for psychoactive drugs.

Original languageEnglish
Article numbere97222
JournalJCI Insight
Volume2
Issue number22
DOIs
StatePublished - Nov 16 2017

Fingerprint

Dive into the research topics of 'Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo'. Together they form a unique fingerprint.

Cite this